EnglishFrançais

Ce site a été mis à jour le 14 mars 2017

Osteoporosis Imprimer
Dennis M. Black, et al (NEJM 25.03.2010) performed secondary analyses using the results of three large, randomized bisphosphonate trials: (FIT, FLEX and the HORIZON Pivotal Fracture Trial in order to evaluate the risk of atypical fractures of the femoral shaft associated with bisphosphonate use. They reviewed fracture records and radiographs (when available) from all hip and femur fractures to identify those below the lesser trochanter and above the distal metaphyseal flare (subtrochanteric and diaphyseal femur fractures) and to assess atypical features. 284 records for hip or femur fractures among 14,195 women in these trials were reviewed. A total of 12 fractures in 10 patients were classified as occurring in the subtrochanteric or diaphyseal femur, a combined rate of 2.3 per 10,000 patient-years. As compared with placebo, the relative hazard was 1.03 (95% CI, 0.06 to 16.46) for alendronate use in the FIT trial, 1.50 (95% CI, 0.25 to 9.00) for zoledronic acid use in the HORIZON-PFT trial, and 1.33 (95% CI, 0.12 to 14.67) for continued alendronate use in the FLEX trial. Although increases in risk were not significant, confidence intervals were wide. The authors concluded that the occurrence of fracture of the subtrochanteric or diaphyseal femur was very rare, even among women who had been treated with bisphosphonates for as long as 10 years. There was no significant increase in risk associated with bisphosphonate use, but the study was underpowered for definitive conclusions.
 
Сделайте правильный выбор! Онлайн или реальные слоты? Играйте на реальные деньги!
займ онлайн